Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints.~* Active plaque psoriasis at screening and baseline.~Exclusion Criteria:~* Non-plaque forms of psoriasis (with exception of nail psoriasis).~* History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06700841 60 mg once daily (Type: EXPERIMENTAL): PF-06700841 60 mg once daily for 52 weeks
- PF-06700841 30 mg once daily (Type: EXPERIMENTAL): PF-06700841 30 mg once daily for 52 weeks
- PF-06700841 10 mg once daily followed by 60 mg once daily (Type: EXPERIMENTAL): PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
- PF-06700841 10 mg once daily followed by 30 mg once daily (Type: EXPERIMENTAL): PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
- Placebo once daily followed by 60 mg once daily (Type: PLACEBO_COMPARATOR): Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
- Placebo once daily followed by 30 mg once daily (Type: PLACEBO_COMPARATOR): Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52

Based on this trial design, predict the completion outcome and termination type (if applicable).